Review




Structured Review

Sequenom oncocarta v.1 massarray system
Oncocarta V.1 Massarray System, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray-system-1/massarray+oncocarta+mutation+profiler+panel/pm20815376-108-8-12
Average 90 stars, based on 1 article reviews
oncocarta v.1 massarray system - by Bioz Stars, 2026-10
90/100 stars

Images

Related Articles

Variant Assay:

Article Title: Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
Article Snippet: .. Scheme year Sample type c.2369C>T p.(Thr790Met) variant allele frequency (%) Method used Laboratory Reason for technical failure 2013 Cell line 25 Cobas EGFR Mutation detection Test v1 (Roche) 1 Inconclusive result 2 No amplification MAD-EGFR mut (Master Diagnostica S. L.) 3 DNA concentration too low EGFR StripAssay (ViennaLab) 4 DNA concentration too low EGFR 29 Mutations Detection Kit (AmoyDx) 5 DNA quality too low EGFR Mutation Analysis Reagents (Applied Biosystems) 6 DNA concentration too low Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 7 Insufficient tissue material for analysis Massarray 4 analyser (Sequenom) 8 DNA concentration too low MassArray OncoCarta panel (Sequenom) 9 Sample did not pass QC Dideoxy sequencing 10 DNA concentration too low 11 Inconclusive result 12 No amplification Pyrosequencing 13 DNA concentration too low High resolution melting 14 No amplification Missing data 15 DNA concentration too low 2014 Cell line 17 Therascreen EGFR pyro Kit (Qiagen DxS) 16 Inconclusive result 2015 Resection 15 Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 17 DNA concentration too low 18 DNA concentration too low Ion AmpliSeq Colon and Lung Cancer Panel (Life technologies) 19 DNA concentration too low Pyrosequencing 20 DNA concentration too low High resolution melting 21 DNA quality too low 2016 Cell line 22 Oncomine Solid Tumour DNA kit (Life Technologies) 16 No amplification 2017 Cell line 20 Cobas EGFR Mutation detection Test v2 (Roche) 22 Insufficient neoplastic cells 23 Insufficient neoplastic cells Cobas EGFR Mutation detection Test v1 (Roche) 24 Insufficient neoplastic cells Dideoxy sequencing 25 Insufficient neoplastic cells ..

Mutagenesis:

Article Title: Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
Article Snippet: .. Scheme year Sample type c.2369C>T p.(Thr790Met) variant allele frequency (%) Method used Laboratory Reason for technical failure 2013 Cell line 25 Cobas EGFR Mutation detection Test v1 (Roche) 1 Inconclusive result 2 No amplification MAD-EGFR mut (Master Diagnostica S. L.) 3 DNA concentration too low EGFR StripAssay (ViennaLab) 4 DNA concentration too low EGFR 29 Mutations Detection Kit (AmoyDx) 5 DNA quality too low EGFR Mutation Analysis Reagents (Applied Biosystems) 6 DNA concentration too low Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 7 Insufficient tissue material for analysis Massarray 4 analyser (Sequenom) 8 DNA concentration too low MassArray OncoCarta panel (Sequenom) 9 Sample did not pass QC Dideoxy sequencing 10 DNA concentration too low 11 Inconclusive result 12 No amplification Pyrosequencing 13 DNA concentration too low High resolution melting 14 No amplification Missing data 15 DNA concentration too low 2014 Cell line 17 Therascreen EGFR pyro Kit (Qiagen DxS) 16 Inconclusive result 2015 Resection 15 Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 17 DNA concentration too low 18 DNA concentration too low Ion AmpliSeq Colon and Lung Cancer Panel (Life technologies) 19 DNA concentration too low Pyrosequencing 20 DNA concentration too low High resolution melting 21 DNA quality too low 2016 Cell line 22 Oncomine Solid Tumour DNA kit (Life Technologies) 16 No amplification 2017 Cell line 20 Cobas EGFR Mutation detection Test v2 (Roche) 22 Insufficient neoplastic cells 23 Insufficient neoplastic cells Cobas EGFR Mutation detection Test v1 (Roche) 24 Insufficient neoplastic cells Dideoxy sequencing 25 Insufficient neoplastic cells ..

Amplification:

Article Title: Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
Article Snippet: .. Scheme year Sample type c.2369C>T p.(Thr790Met) variant allele frequency (%) Method used Laboratory Reason for technical failure 2013 Cell line 25 Cobas EGFR Mutation detection Test v1 (Roche) 1 Inconclusive result 2 No amplification MAD-EGFR mut (Master Diagnostica S. L.) 3 DNA concentration too low EGFR StripAssay (ViennaLab) 4 DNA concentration too low EGFR 29 Mutations Detection Kit (AmoyDx) 5 DNA quality too low EGFR Mutation Analysis Reagents (Applied Biosystems) 6 DNA concentration too low Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 7 Insufficient tissue material for analysis Massarray 4 analyser (Sequenom) 8 DNA concentration too low MassArray OncoCarta panel (Sequenom) 9 Sample did not pass QC Dideoxy sequencing 10 DNA concentration too low 11 Inconclusive result 12 No amplification Pyrosequencing 13 DNA concentration too low High resolution melting 14 No amplification Missing data 15 DNA concentration too low 2014 Cell line 17 Therascreen EGFR pyro Kit (Qiagen DxS) 16 Inconclusive result 2015 Resection 15 Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 17 DNA concentration too low 18 DNA concentration too low Ion AmpliSeq Colon and Lung Cancer Panel (Life technologies) 19 DNA concentration too low Pyrosequencing 20 DNA concentration too low High resolution melting 21 DNA quality too low 2016 Cell line 22 Oncomine Solid Tumour DNA kit (Life Technologies) 16 No amplification 2017 Cell line 20 Cobas EGFR Mutation detection Test v2 (Roche) 22 Insufficient neoplastic cells 23 Insufficient neoplastic cells Cobas EGFR Mutation detection Test v1 (Roche) 24 Insufficient neoplastic cells Dideoxy sequencing 25 Insufficient neoplastic cells ..

Concentration Assay:

Article Title: Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
Article Snippet: .. Scheme year Sample type c.2369C>T p.(Thr790Met) variant allele frequency (%) Method used Laboratory Reason for technical failure 2013 Cell line 25 Cobas EGFR Mutation detection Test v1 (Roche) 1 Inconclusive result 2 No amplification MAD-EGFR mut (Master Diagnostica S. L.) 3 DNA concentration too low EGFR StripAssay (ViennaLab) 4 DNA concentration too low EGFR 29 Mutations Detection Kit (AmoyDx) 5 DNA quality too low EGFR Mutation Analysis Reagents (Applied Biosystems) 6 DNA concentration too low Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 7 Insufficient tissue material for analysis Massarray 4 analyser (Sequenom) 8 DNA concentration too low MassArray OncoCarta panel (Sequenom) 9 Sample did not pass QC Dideoxy sequencing 10 DNA concentration too low 11 Inconclusive result 12 No amplification Pyrosequencing 13 DNA concentration too low High resolution melting 14 No amplification Missing data 15 DNA concentration too low 2014 Cell line 17 Therascreen EGFR pyro Kit (Qiagen DxS) 16 Inconclusive result 2015 Resection 15 Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 17 DNA concentration too low 18 DNA concentration too low Ion AmpliSeq Colon and Lung Cancer Panel (Life technologies) 19 DNA concentration too low Pyrosequencing 20 DNA concentration too low High resolution melting 21 DNA quality too low 2016 Cell line 22 Oncomine Solid Tumour DNA kit (Life Technologies) 16 No amplification 2017 Cell line 20 Cobas EGFR Mutation detection Test v2 (Roche) 22 Insufficient neoplastic cells 23 Insufficient neoplastic cells Cobas EGFR Mutation detection Test v1 (Roche) 24 Insufficient neoplastic cells Dideoxy sequencing 25 Insufficient neoplastic cells ..

Polymerase Chain Reaction:

Article Title: Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
Article Snippet: .. Scheme year Sample type c.2369C>T p.(Thr790Met) variant allele frequency (%) Method used Laboratory Reason for technical failure 2013 Cell line 25 Cobas EGFR Mutation detection Test v1 (Roche) 1 Inconclusive result 2 No amplification MAD-EGFR mut (Master Diagnostica S. L.) 3 DNA concentration too low EGFR StripAssay (ViennaLab) 4 DNA concentration too low EGFR 29 Mutations Detection Kit (AmoyDx) 5 DNA quality too low EGFR Mutation Analysis Reagents (Applied Biosystems) 6 DNA concentration too low Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 7 Insufficient tissue material for analysis Massarray 4 analyser (Sequenom) 8 DNA concentration too low MassArray OncoCarta panel (Sequenom) 9 Sample did not pass QC Dideoxy sequencing 10 DNA concentration too low 11 Inconclusive result 12 No amplification Pyrosequencing 13 DNA concentration too low High resolution melting 14 No amplification Missing data 15 DNA concentration too low 2014 Cell line 17 Therascreen EGFR pyro Kit (Qiagen DxS) 16 Inconclusive result 2015 Resection 15 Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 17 DNA concentration too low 18 DNA concentration too low Ion AmpliSeq Colon and Lung Cancer Panel (Life technologies) 19 DNA concentration too low Pyrosequencing 20 DNA concentration too low High resolution melting 21 DNA quality too low 2016 Cell line 22 Oncomine Solid Tumour DNA kit (Life Technologies) 16 No amplification 2017 Cell line 20 Cobas EGFR Mutation detection Test v2 (Roche) 22 Insufficient neoplastic cells 23 Insufficient neoplastic cells Cobas EGFR Mutation detection Test v1 (Roche) 24 Insufficient neoplastic cells Dideoxy sequencing 25 Insufficient neoplastic cells ..

Sequencing:

Article Title: Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
Article Snippet: .. Scheme year Sample type c.2369C>T p.(Thr790Met) variant allele frequency (%) Method used Laboratory Reason for technical failure 2013 Cell line 25 Cobas EGFR Mutation detection Test v1 (Roche) 1 Inconclusive result 2 No amplification MAD-EGFR mut (Master Diagnostica S. L.) 3 DNA concentration too low EGFR StripAssay (ViennaLab) 4 DNA concentration too low EGFR 29 Mutations Detection Kit (AmoyDx) 5 DNA quality too low EGFR Mutation Analysis Reagents (Applied Biosystems) 6 DNA concentration too low Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 7 Insufficient tissue material for analysis Massarray 4 analyser (Sequenom) 8 DNA concentration too low MassArray OncoCarta panel (Sequenom) 9 Sample did not pass QC Dideoxy sequencing 10 DNA concentration too low 11 Inconclusive result 12 No amplification Pyrosequencing 13 DNA concentration too low High resolution melting 14 No amplification Missing data 15 DNA concentration too low 2014 Cell line 17 Therascreen EGFR pyro Kit (Qiagen DxS) 16 Inconclusive result 2015 Resection 15 Therascreen EGFR RGQ PCR Kit (Qiagen DxS) 17 DNA concentration too low 18 DNA concentration too low Ion AmpliSeq Colon and Lung Cancer Panel (Life technologies) 19 DNA concentration too low Pyrosequencing 20 DNA concentration too low High resolution melting 21 DNA quality too low 2016 Cell line 22 Oncomine Solid Tumour DNA kit (Life Technologies) 16 No amplification 2017 Cell line 20 Cobas EGFR Mutation detection Test v2 (Roche) 22 Insufficient neoplastic cells 23 Insufficient neoplastic cells Cobas EGFR Mutation detection Test v1 (Roche) 24 Insufficient neoplastic cells Dideoxy sequencing 25 Insufficient neoplastic cells ..

other:

Article Title: FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
Article Snippet: Supporting this concept, Hernandez and colleagues recently performed comparative analyses of known cancer genes using microarray-based comparative genomic hybridization and Sequenom MassARRAY (OncoCarta Panel v 1.0, Sequenom, San Diego, CA, USA) in matched DCIS and adjacent invasive carcinomas, and suggested that although the modal populations of both components were similar at the genetic level, the progression from DCIS to invasive ductal carcinoma was driven in some cases by selection of nonmodal clones with specific genetic aberrations [ ].

Article Title: An anaplastic lymphoma kinase (ALK) immunohistochemistry negative but fluorescence in situ hybridization (FISH) positive lung adenocarcinoma is resistant to Crizotinib
Article Snippet: Mutation profiling was performed using the OncoCarta v.1 MassArray platform (Sequenom, San Diego, CA).

Article Title: Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children’s Oncology Group
Article Snippet: All 52 cases were assayed using the Sequenom MassARRAY OncoCarta v1.0 and v3.0 panels (Sequenom, San Diego, CA), according to manufacturer’s specifications, to examine 365 unique mutations in 33 cancer-related genes.

Article Title: Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
Article Snippet: From those individuals with sufficient available archival tumor tissue, gene mutational analysis was carried out on DNA extracted from archival tumor samples using PyroMark ® PCR or Sequenom MassARRAY OncoCarta ® platform according to the manufacturer’s protocol.

Article Title: Low-risk DCIS. What is it? Observe or excise?
Article Snippet: There is, however, increasing evidence that intratumoural genetic heterogeneity is present in some DCIS [ ]; in one small series, thorough analysis including microarray-based comparative genomic hybridization (aCGH), Sequenom MassARRAY (Oncocarta v 1.0 panel), fluorescence in situ hybridization and Sanger sequencing found that, in a proportion of cases, amplification of distinct loci (i.e. 1q41, 2q24.2, 6q22.31, 7q11.21, 8q21.2 and 9p13.3) was either restricted to, or more frequent in, a population of cancer cells in either the DCIS or invasive disease in paired frozen samples.



Similar Products

96
agena bioscience massarray system
Massarray System, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray-system-1/Methylation/pm30940696-99-1-3
Average 96 stars, based on 1 article reviews
massarray system - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

96
agena bioscience massarray system methylation detection amplification pcr reaction
Massarray System Methylation Detection Amplification Pcr Reaction, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray-system-1/Methylation/pm31002356-111-8-15
Average 96 stars, based on 1 article reviews
massarray system methylation detection amplification pcr reaction - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

96
agena bioscience agena massarray system methylation detection amplification pcr reaction
Agena Massarray System Methylation Detection Amplification Pcr Reaction, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray-system-1/Methylation/pm31002356-111-7-15
Average 96 stars, based on 1 article reviews
agena massarray system methylation detection amplification pcr reaction - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

90
Sequenom oncocarta v.1 massarray system
Oncocarta V.1 Massarray System, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray-system-1/massarray+oncocarta+mutation+profiler+panel/pm20815376-108-8-12
Average 90 stars, based on 1 article reviews
oncocarta v.1 massarray system - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results